Medical Cannabis Operators Can Finally Run Their Business Like a Business.

Let’s consider what just happened a month ago. On April 22, 2026, the Department of Justice issued a final order placing state-licensed medical marijuana into Schedule III of the Controlled Substances Act. After years of false starts, stalled hearings, a fired attorney general, and a president who, the previous weekend, told officials to stop “slow-walking” the process, the order is real, it is final, and it is effective now.

The immediate practical consequence for operators holding a state medical marijuana license: starting with tax year 2026, Section 280E of the Internal Revenue Code no longer applies to your licensed operations. Section 280E is the provision that has prohibited cannabis businesses from deducting ordinary business expenses—payroll, rent, utilities, equipment, professional services—because those expenses were incurred in the trafficking of a Schedule I or II controlled substance. With medical cannabis now in Schedule III, that disallowance is lifted.

This is genuinely good news. It is also not the finish line.

Admittedly, the cannabis industry has been let down before by regulatory signals that didn’t materialize, and there are real caveats here worth understanding before you do anything. But for medical cannabis operators—growers, processors, dispensaries holding state medical licenses—the tax environment has structurally changed. The question worth your attention right now is not whether to celebrate. It’s what to do with the runway you’ve just been handed.

What Changed, and What Didn’t

The DOJ order is specific. It covers FDA-approved marijuana products and marijuana “subject to a qualifying state-issued medical marijuana license.” As of today, 39 states plus the District of Columbia have operational medical marijuana programs. If your operation holds one of those state licenses, you are out from under 280E—effective for the full 2026 tax year, and maybe retroactively.

Dual License

What it does not cover: adult-use or recreational cannabis. If you operate in a dual-license state and your medical and adult-use activities are commingled, you face a harder question. Operators in that position will need to carefully segregate their medical and adult-use revenue and expenses, because the adult-use side remains in Schedule I, and 280E still applies there. Encouragingly, the Treasury and the IRS have announced that formal guidance is forthcoming on exactly how to do that apportionment—be on the lookout for it. This signal from Treasury holds the promise that having some recreational activities may not reinvoke 280E for the entire business. 

Prognosis on Recreational?

And the path to broader rescheduling of all cannabis—recreational included—is not closed. The DEA has announced an expedited administrative hearing beginning June 29, 2026, to address full Schedule I to Schedule III redesignation. If that process proceeds on the DOJ’s timeline, a final rule covering adult-use operations could come as soon as late 2026, though legal challenges could extend that horizon. But given that many perceive that full descheduling would be a tailwind for the November elections, it could happen early fall.

Prior Years

One more important detail for those wondering about prior years: the DOJ order expressly encourages the Treasury Secretary to consider retroactive relief from 280E for taxable years when operators were state-licensed. The Treasury and IRS have acknowledged this and say guidance is coming. However, their initial position is that rescheduling applies to the full taxable year that includes the April 22, 2026, effective date—meaning 2026 is the first clean year, not 2025. Retroactive relief for 2022–2025 is possible, but it is not guaranteed and will require further guidance before anyone should bank on it. 

Prepare Now

If you hold a state medical marijuana license, 280E is no longer for 2026. If you operate both medical and adult-use, you need to get your accounting systems ready to segregate those activities, and you will want to do it now so you are ready. Plus, it is good business to track expenses across both Medical and Recreational separately (at least in a project accounting way, if not corporate division way), so the company can manage its business like a business. Medical and Recreational appeal to similar, but different audiences. This needs to be reflected in its financials as well as product development and marketing.

The Yoke Is Off. Don’t Just Breathe—Invest.

The natural reaction to years of punishing taxes is relief. And relief is warranted. But the operators who come out of this period strongest won’t be the ones who simply enjoy the improved cash flow. They’ll be the ones who redeploy it.

Under 280E, cannabis businesses were effectively taxed on gross profit—not net income—because most operating expenses couldn’t be deducted. Effective federal tax rates in the 50–70% range were not unusual. That’s not a tax burden; that’s a structural impediment to investment. Businesses that would have expanded, modernized, or launched new products instead had capital absorbed by taxes, or worse, built up an extremely large tax liability.

That dynamic is over for medical operators. The question now is what to build.

Facility Builds and Plant Expansions: The Overlooked Credit Opportunity

Here is something most cannabis operators—and many of their advisors—don’t know or fully appreciate: facility builds, plant expansions, and processing facility modernizations are among the most productive activities for generating R&D tax credits, yet they are chronically underutilized and underclaimed across all manufacturing, especially in this industry—we have successfully claimed state credits for our cannabis clients since pre-COVID. Now, owners going forward can pick up federal credits too.

The conventional wisdom has been that conducting an R&D study on facility-related projects is one where “the juice isn’t worth the squeeze.” That narrow view on the opportunity cost operators real money. When the activities are analyzed by R&D specialists who know how to build the substantiation for a facility project, the credits can be substantial.

Numbers Example

To put numbers to it: on a $35 million buildout of a grow and processing facility, a properly conducted R&D study should generate approximately $2 million in federal R&D credits and, depending on the state, an additional $600,000 in state credits. That is $2.6 million in credits on a project that many operators would never have given serious attention. And because 280E had previously barred any federal tax benefit, few ever pursued a study—though the state credit opportunity has been very much open, and the operators who previously moved on it over the years have a head start.

With 280E lifted, federal R&D credits are now actually usable. And for states with their own medical cannabis programs—many of which have robust state R&D credit regimes—the opportunity is expanded.

If you are planning a facility expansion, plant modernization, or new processing build, engage an R&D tax specialist early in the process rather than after. While the best time to engage a provider is during the build-out, the next best time is now for any facility work performed over the last three years, as these might be available depending on the DOJ and Treasury’s final guidance. Please note that the best providers will do the heavy lifting by working with your general contractor and subcontractors to track down the information needed for proper substantiation.

Product Development: The Credits Hidden in Your Grow Room

The race to the highest THC percentage has been the dominant product strategy in cannabis for years. For many operators, it’s also been the only strategy—not necessarily by choice, but by constraint. When your effective tax rate is north of 50%, you don’t invest in differentiation. You survive.

Medical cannabis operators now have both the financial headroom and the scientific rationale to accelerate the building of product suites that compete on something other than potency. The science around cannabinoids, terpenes, and their interactions is still evolving, and the medical use case—the one that just got federal recognition—rewards operators who can substantiate specific therapeutic profiles, not just THC content.

This kind of product development is exactly what the R&D tax credit was designed to incentivize. Think about what Miller did when it developed Miller Lite: it didn’t just make beer with lower calories. It systematically reformulated a product to hit specific sensory and performance targets, and that process—experimentation, iteration, testing, failure, refinement—is the definition of qualified research. Cannabis producers building differentiated product lines around specific cannabinoid ratios, terpene profiles, or delivery mechanisms are doing the same thing.

Every grow cycle runs as a controlled experiment comparing inputs, environments, and outputs. Every extraction protocol is developed in-house. Every new form factor—tincture, topical, edible, sublingual—is developed and tested for consistency and efficacy. These activities generate R&D credits. Most cannabis operators have never claimed them, and many of their advisors have never told them they could or should.

Product development isn’t just a growth strategy. Under the R&D tax credit framework, it’s a tax strategy. The two are now aligned in a way they never could be under 280E.

A Note on Timing and Caution

Yes, the order is real. Yes, it is in effect. And yes, legal challenges are expected. The acting attorney general invoked a specific legal authority—the obligation to carry out U.S. treaty commitments under the Single Convention on Narcotic Drugs—as the basis for issuing the order without ordinary notice-and-comment rulemaking. That procedural shortcut is exactly what opponents will challenge in court.

The DEA included a severability clause in the order, meaning that if one provision is struck down, the rest survives. That is a meaningful protection. But cannabis operators have learned, sometimes expensively, not to make new major financial commitments based on regulatory signals that are still subject to challenge.

Follow the River

The right posture is this: plan as if the order will hold, because the direction of travel is unmistakable and the political will behind it is strong. But structure your investments so that they make business sense independent of any particular tax outcome. An expansion that only pencils out because of R&D credits is a weak investment. An expansion that makes sense on its own and generates significant credits as a result is a good one.

The river of history on cannabis is flowing toward full legalization. The executive order, the DOJ action, the expedited hearing, and the Treasury guidance in process all point that same way. For state-licensed medical operators, the question is no longer whether relief is coming; it’s how fast you can move now that it’s here.

What to Do This Month

•  Get your accounting systems ready to segregate medical and adult-use activities. If you operate both, this is not optional. Treasury guidance will formalize the requirement, but the time to build those systems is before the guidance arrives, not after, to be one of the early movers.

•  Talk to an R&D tax specialist about any current or planned facility investments. Before you finalize plans for a new grow room, processing expansion, or equipment installation, understand what qualifies—think custom-engineered equipment & systems— and how to document it. The credits on a $10M–$50M build are not trivial.

•  Revisit your product development roadmap with R&D credits in mind. If you have been avoiding investments in product differentiation because the tax math didn’t work, that constraint is gone. The activities you’ve already been doing—and the ones you’ve been deferring—deserve a fresh look.

•  The window on 2022 is closing. Prepare now for a 2022 claim in case the retroactive relief comes to be. The 2022 return falls out of statute 3 years from the date filed. For most cannabis operators, that means mid to late this summer. The IRS has not yet issued formal guidance on prior-year 280E recovery. But the DOJ order explicitly encouraged it, and Treasury is working on it. Filing protective claims or amended returns would be advisable. This requires a qualified advisor before acting.

Medical cannabis operators have been running with a significant structural disadvantage for years—not because their businesses were weak, but because the tax code treated them as if they were criminals rather than companies. That is changing. The operators who move deliberately now, invest in their facilities and their products, and claim the credits the law has always permitted will look back on April 2026 as the inflection point. An ounce of planning right now is worth ten pounds of catch-up later.

Author Information

Rick Kleban is the founder and president of Sycamore Growth Group. He also advocates at the federal and state levels to improve the credit to better incentivize innovation, which, in turn, grows the tax base and helps communities.

James Bean, CPA, is a senior researcher and R&D tax controversy specialist at Sycamore Growth Group.

Jenna Tugaoen is a tax attorney at Sycamore Growth Group who specializes in assisting businesses in obtaining and substantiating R&D tax credits and resolving tax controversies.

Sycamore Growth Group is an Ohio-based firm specializing in federal and state research & development tax credits by providing elite written substantiation for credit claims.